NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company had earlier announced about the approval received from the MHRA for Liraglutide
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Yesafili, received marketing authorization approval from the European Commission for the European Union
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Lutio has the potential to offer significant cost savings when available to UK patients.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)